Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases ...

From May 30, 2025 through June 12, 2025, SharpLink sold shares under its $1 billion ATM equity program, and thus far has raised approximately $79 million in gross proceeds, a majority of which it ...